1. Home
  2. BNR vs ABOS Comparison

BNR vs ABOS Comparison

Compare BNR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$8.62

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$2.39

Market Cap

165.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
ABOS
Founded
2014
1996
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.7M
165.4M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BNR
ABOS
Price
$8.62
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.00
AVG Volume (30 Days)
17.5K
312.2K
Earning Date
06-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$1.05
52 Week High
$41.72
$3.60

Technical Indicators

Market Signals
Indicator
BNR
ABOS
Relative Strength Index (RSI) 28.99 49.80
Support Level $8.04 $2.14
Resistance Level $9.70 $2.42
Average True Range (ATR) 1.17 0.14
MACD -0.06 0.00
Stochastic Oscillator 7.02 49.61

Price Performance

Historical Comparison
BNR
ABOS

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: